Congressos e publicações

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study Systematic literature review of unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Similar ibrutinib (ibru) efficacy across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia (R/R CLL): Matching-adjusted indirect comparison (MAIC)

Similar ibrutinib (ibru) efficacy across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia (R/R CLL): Matching-adjusted indirect comparison (MAIC)

Considerations to ensure transportability when using open claims data to conduct natural history and event rate estimation studies

Considerations to ensure transportability when using open claims data to conduct natural history and event rate estimation studies

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC) BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

Number-needed-to-treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia

Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies

Physician-reported treatment patterns and outcomes in marginal zone lymphoma in South Korea

Physician-reported treatment patterns and outcomes in marginal zone lymphoma in South Korea Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies